Cargando…

Overexpression of MDM2 in MCF‐7 Promotes Both Growth Advantage and p53 Accumulation in Response to Estradiol

The overexpression of the oncogene product MDM2 is often observed in human breast cancer cells, especially in estrogen receptor (ER)‐positive ones. To study the role of MDM2 protein in ER‐positive breast cancer, we have established cell lines derived from MCF‐7 which stably express increased and dec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saji, Shigehira, Nakashima, Shigeru, Hayashi, Shin‐ichi, Toi, Masakazu, Saji, Shigetoyo, Nozawa, Yoshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1999
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926053/ https://www.ncbi.nlm.nih.gov/pubmed/10189892 http://dx.doi.org/10.1111/j.1349-7006.1999.tb00735.x

Ejemplares similares

Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
por: Okumura, Naoki, et al.
Publicado: (2002)

Role of MDM2 Overexpression in Doxorubicin Resistance of Breast Carcinoma
por: Suzuki, Akio, et al.
Publicado: (1998)

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7
por: Suga, Junko, et al.
Publicado: (2018)

Impact of body mass index on breast cancer in accordance with the life-stage of women
por: Suzuki, Reiko, et al.
Publicado: (2012)

Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network
por: Kiso, Marina, et al.
Publicado: (2018)

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
por: Ueno, Takayuki, et al.
Publicado: (2019)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Circulating cell-free DNA-based epigenetic assay can detect early breast cancer
por: Uehiro, Natsue, et al.
Publicado: (2016)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)
por: Ishiguro, Hiroshi, et al.
Publicado: (2017)

Centrosomal Kinases, HsAIRK1 and HsAIRK3, are Overexpressed in Primary Colorectal Cancers
por: Takahashi, Takao, et al.
Publicado: (2000)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Molecular Analysis of a Myc Antagonist, ROX/Mnt, at 17p13.3 in Human Lung Cancers
por: Takahashi, Takao, et al.
Publicado: (1998)

Trend in Cancer Incidence and Mortality in Fukushima From 2008 Through 2015
por: Shibata, Akiko, et al.
Publicado: (2021)

Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy
por: Honma, Naoko, et al.
Publicado: (2015)

A Simple Method for Classification of Cell Death by Use of Thin Layer Collagen Gel for the Detection of Apoptosis and/or Necrosis after Cancer Chemotherapy
por: Matsuo, Atsushi, et al.
Publicado: (2001)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

MDM2 Overexpression with Alteration of the p53 Protein and Gene Status in Oral Carcinogenesis
por: Li, Xiao‐Jun, et al.
Publicado: (2000)

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
por: Ueno, Takayuki, et al.
Publicado: (2016)

Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations
por: Yu, Qiong, et al.
Publicado: (2014)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Tumorigenesis promotes Mdm4-S overexpression
por: Pant, Vinod, et al.
Publicado: (2017)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer
por: Swetzig, Wendy M., et al.
Publicado: (2016)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels
por: Alkhalaf, Moussa, et al.
Publicado: (2005)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
por: Toi, Masakazu, et al.
Publicado: (2010)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
por: Uematsu, Takayoshi, et al.
Publicado: (2021)

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
por: Uematsu, Takayoshi, et al.
Publicado: (2019)

HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels
por: Wang, Ying, et al.
Publicado: (2001)

Detection of P53 and Mdm2 in vitiligo
por: Wiwanitkit, Viroj
Publicado: (2013)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s3c4497ec3pfj9uol3k16oj8kf